Drugs targeting intermediate filaments can improve neurosupportive properties of astrocytes

Accepted Manuscript Title: Drugs targeting intermediate filaments can improve neurosupportive properties of astrocytes Authors: Yolanda de Pablo, Meng Chen, Elin M¨ollerstr¨om, Marcela Pekna, Milos Pekny PII: DOI: Reference:

S0361-9230(17)30049-7 http://dx.doi.org/doi:10.1016/j.brainresbull.2017.01.021 BRB 9161

To appear in:

Brain Research Bulletin

Received date: Revised date: Accepted date:

14-10-2016 15-1-2017 27-1-2017

Please cite this article as: Yolanda de Pablo, Meng Chen, Elin M¨ollerstr¨om, Marcela Pekna, Milos Pekny, Drugs targeting intermediate filaments can improve neurosupportive properties of astrocytes, Brain Research Bulletin http://dx.doi.org/10.1016/j.brainresbull.2017.01.021 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Drugs targeting intermediate filaments can improve neurosupportive properties of astrocytes

Yolanda de Pablo1*, Meng Chen1, Elin Möllerström1, Marcela Pekna1,2,3 and Milos Pekny1,2,3* 1

Center for Brain Repair and Rehabilitation, Department of Clinical Neuroscience

and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden 2

Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia

3

University of Newcastle, New South Wales, Australia

*

Correspondence to Dr. Yolanda de Pablo or Prof. Milos Pekny

Center for Brain Repair and Rehabilitation, Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Box 440, 40530 Gothenburg. e-mail: [email protected], [email protected]

Key words Intermediate filaments (nanofilaments), astrocytes, neuroprotection, oxygen and glucose deprivation, oxidative stress

Highlights Clomipramine lowers GFAP, vimentin and nestin protein level in astrocytes in vitro Clomipramine and epoxomicin increase in vitro neurosupportive effects of astrocytes Clomipramine and epoxomicin do not adversely affect astrocyte resilience to OGD

Abbreviations CNS, central nervous system; GFAP, glial fibrilary acidic protein; OGD, oxygenglucose deprivation

1

ABSTRACT In response to central nervous system (CNS) injury, astrocytes upregulate intermediate filament (nanofilament) proteins GFAP and vimentin. Whereas the intermediate filament upregulation in astrocytes is important for neuroprotection in the acute phase of injury, it might inhibit the regenerative processes later on. Thus, timely modulation of the astrocyte intermediate filaments was proposed as a strategy to promote brain repair. We used clomipramine, epoxomicin and withaferin A, drugs reported to decrease the expression of GFAP, and assessed their effect on neurosupportive properties and resilience of astrocytes to oxygen and glucose deprivation (OGD). Clomipramine decreased protein levels of GFAP, as well as vimentin and nestin, and did not affect astrocyte resilience to oxidative stress. Withaferin A sensitized astrocytes to OGD. Both clomipramine and epoxomicin promoted the attachment and survival of neurons co-cultured with astrocytes under standard culture conditions. Moreover, epoxomicin increased neurosupportive properties of astrocytes after OGD. Our data point to clomipramine and epoxomicin as potential candidates for astrocyte modulation to improve outcome after CNS injury.

2

1. INTRODUCTION Astrocytes are activated in response to various CNS injuries. This phenomenon is known as reactive gliosis and is characterized by hypertrophy of astrocyte processes, altered expression of many genes including upregulation of cytoplasmic intermediate filament proteins (known also as nanofilament proteins) glial fibrillary acidic protein (GFAP), vimentin and nestin, increased cell proliferation, and release of molecules modulating inflammation and post-traumatic remodeling (Jing et al. 2007, Parpura et al. 2012, Pekny & Nilsson 2005, Pekny & Pekna 2014, Pekny et al. 2014a, Pekny et al. 2016, Sofroniew & Vinters 2010, Sofroniew 2009, Wilhelmsson et al. 2006, Zhang et al. 2016). Mice deficient in GFAP and vimentin (GFAP–/–Vim–/–) exhibit attenuated reactive gliosis (Eliasson et al. 1999, Pekny et al. 1999). Experiments with mice with modulated reactive gliosis (GFAP–/–Vim–/– mice and mice with astrocytespecific ablation of STAT3 or Socs3) suggested that reactive astrocytes have a positive role in neuroprotection and confinement of the lesion area in models of brain injury (Pekny et al. 1999, Wilhelmsson et al. 2004), ischemic stroke (Li et al. 2008), retinal ischemia (Wunderlich et al. 2015), or spinal cord injury (Herrmann et al. 2008, Okada et al. 2006). Interestingly, GFAP–/–Vim–/– mice exhibit better posttraumatic regeneration of neuronal synapses (Wilhelmsson et al. 2004) and axons (Cho et al. 2005), improved functional recovery after spinal cord injury (Menet et al. 2003), reduced photoreceptor degeneration in a retinal detachment model (Nakazawa et al. 2007), and reduced pathological neovascularization in oxygen-induced retinopathy (Lundkvist et al. 2004). In addition, in GFAP–/–Vim–/– mice, retinal grafts are better integrated (Kinouchi et al. 2003), differentiation of transplanted neural stem cells into neurons and astrocytes is enhanced (Widestrand et al. 2007), and hippocampal neurogenesis is increased under physiological conditions (Larsson et al. 2004, Wilhelmsson et al. 2012), after neonatal hypoxic-ischemic injury (Jarlestedt et al. 2010), or after neurotrauma (Wilhelmsson et al. 2012). Albeit the mechanisms linking the astrocyte intermediate filament system to CNS regeneration and plasticity are far from being understood, the intermediate filament system was shown to be important for intracellular vesicle trafficking (Potokar et al. 2010, Potokar et al. 2007, Vardjan et al. 2012), and the differentiation inhibitory Notch signaling from astrocytes to neural stem/progenitor cells is reduced in intermediate filament-free astrocytes

3

(Lebkuechner et al. 2015, Wilhelmsson et al. 2012). Thus, in a variety of injury models, the benefits of reactive gliosis in the acute stage of CNS injury might be balanced against the restricted regenerative potential later on, and hence modulation of reactive gliosis targeting the intermediate filament system might lead to enhanced recovery after CNS injury (Pekny & Pekna 2014, Pekny et al. 2014a).

The intermediate filament system is regulated at multiple levels. Different intermediate filament proteins can be found in the same cell as a soluble pool of subunits that polymerize to form the filaments. Filaments can also elongate by annealing of already formed filaments, and subunits can be exchanged along the filament (Colakoglu & Brown 2009). Intermediate filament assembly and disassembly are regulated by phosphorylation (Eriksson et al. 2004, Inagaki et al. 1990, Takemura et al. 2002). Intermediate filament assembly depends on active transport of subunits to the cell areas where the filament extension takes place (Helfand et al. 2004, Prahlad et al. 1998), and binding to regulatory proteins such as 14-3-3gamma (Li et al. 2006) or plectin (Spurny et al. 2007). In addition, some intermediate filament proteins expressed in the CNS undergo alternative splicing (Izmiryan et al. 2006, Middeldorp & Hol 2011, Wong et al. 2013). Accumulation of intermediate filament proteins and intermediate filaments was linked to several diseases affecting the skin, muscle and CNS as well as other tissues (Goldman & Yen 1986, Liem & Messing 2009, McLean & Lane 1995, Paulin et al. 2004, Worman & Courvalin 2002). GFAP mutations that lead to GFAP overexpression, accumulation of disorganized intermediate filaments and formation of Rosenthal fibers are causative of Alexander disease (Brenner et al. 2001).

In vitro, overexpression of GFAP leads to Rosenthal fiber formation, disruption of the cytoskeleton, decrease in astrocyte proliferation, increased cell death, reduction of proteasomal function, and impairment of astrocyte resistance to oxidative stress (Cho & Messing 2009). Several drugs were reported to decrease GFAP expression in vitro and in vivo (Bargagna-Mohan et al. 2010, Cho et al. 2010, Middeldorp et al. 2009). Clomipramine (8 µM) treatment of astrocyte cultures for 10 days decreased the amount of GFAP by 50% (Cho et al. 2010), but its effect on other intermediate filament proteins of astrocytes is unknown. Epoxomicin, and other proteasome inhibitors, decreased GFAP mRNA and soluble protein levels in human astrocytoma 4

U343 cells at doses ranging from 5 to 100 nM as well as GFAP protein levels in a rat model for induced astrogliosis (Middeldorp et al. 2009). In astrocyte cultures, withaferin A downregulated soluble vimentin and GFAP at 0.5 µM and systemic delivery of withaferin A down-regulated expression of both vimentin and GFAP in mouse retinas (Bargagna-Mohan et al. 2010). None of these drugs has been assessed as potential modulator of neurosupportive properties of astrocytes. We hypothesize that pharmacological modulation of the astrocyte intermediate filament system improves neuroregeneration after CNS injury. Here, we have examined the effect of epoxomicin, clomipramine and withaferin A on astrocyte resilience to ischemic stress in vitro, and astrocyte neurosupportive properties, both under standard conditions and after OGD, an in vitro ischemia model.

2. METHODS 2.1. Reagents Epoxomicin was purchased from Cayman Chemical Company (Ann Arbor, MI, USA) as a 180.3 µM solution in DMSO. Clomipramine hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) stock solution was prepared in water at 50 mM. Stock solution of Withaferin A (Sigma-Aldrich) 4.25 mM was prepared in DMSO. Trypsin, HBSS, penicillin/streptomycin, Neurobasal, and L-glutamine were purchased from Gibco (Life technologies, Paisley, UK). DMEM, and poly-D-Lysine hydrobromide were purchased from Sigma-Aldrich. TrypLE and B27, were purchased from Gibco (Life technologies, Grand Island, NY, USA).

2.2. Animals Wild-type mice and mice carrying a null mutation in the GFAP and vimentin genes GFAP–/–Vim–/– (Colucci-Guyon et al. 1994, Eliasson et al. 1999, Pekny et al. 1995) were on a mixed C57Bl6/129 Sv/129Ola genetic background. All mice were housed in a barrier facility, and experiments were conducted according to protocols approved by the Ethics Committee of the University of Gothenburg.

2.3. Cell cultures All cell culture media were supplemented with 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Standard culture conditions were 5% CO2, 37 °C, in a humidified incubator. Multi-well plates were from TPP Techno Plastic 5

Products AG (Trasadingen, Switzerland), flasks were from Sarstedt (Newton, NC, USA). Cortical astrocyte enriched cultures were prepared from postnatal day 0.5 to day 2.5 mice as described before (Pekny et al. 1998, Stahlberg et al. 2011). After decapitation, the brains were dissected under sterile conditions. Cortices were isolated in PBS, freed from meninges, and incubated for 10 min at 37 °C in 0.25% trypsin solution. Trypsin was removed and tissue samples were mechanically dissociated in DMEM supplemented with 10% FBS (Hyclone, South Logan, UT, USA). The cell suspension was plated on poly-D-lysine coated 75 cm2 flasks at the plating density of one set of cortices per flask. Every other day, the cultures were shaken and the media replaced. Cultures typically reached confluence at 7 days in vitro, at this point, the cells were detached by incubation in TrypLE at 37 °C for 10 min. Cells were pelleted by centrifugation at 253 g and replated on poly-D-lysine coated plates at a density of 25,000 cells/cm2. Neuron enriched cultures were prepared from embryonic cortices at day 17.5 of gestation. Pregnant mice were killed and embryos decapitated. Embryonic cortices were dissected and freed from meninges, washed twice in cold HBSS and incubated in 0.25% trypsin for 10 min at 37 °C. Trypsin was removed and DMEM supplemented with 10% FBS and 50 µg/ml DNase1 was added. Mechanical dissociation was gently performed with a fire-polished Pasteur pipette. The cell suspension was passed through a 40 µm mesh and seeded on poly-D-lysine coated plates or on top of astrocyte monolayers at a density of 80,000 or 21,300 cells/cm2 respectively. Co-cultures were maintained in neurobasal supplemented with B27.

2.4. Western blot analysis At the end of treatment, astrocyte cultures were rinsed in ice-cold PBS and lysed in 2% SDS, 65 mM Tris pH 6.8. Equal amounts of protein (30 µg), were run on precast Any KD gels (Bio-Rad, Hercules, California, USA) and transferred to PVDF membranes according to manufacturer's instructions. Membranes were incubated with rabbit anti GFAP (Dako, Glostrup, Denmark), rabbit anti vimentin (Abcam, Cambridge, UK) and mouse anti nestin (BD Transduction Laboratories) antibodies at a 1:2,000 dilution in TBST overnight at 4°C, followed by 1 h incubation at room temperature with horseradish peroxidase (HRP)-linked antibodies and developed with enhanced chemiluminescence detection reagent (Amersham, GE Healthcare UK,

6

Buckinghamshire, UK). GAPDH antibodies linked to HRP were incubated for 1 h at room temperature. Anti mouse IgG, anti rabbit IgG and anti GAPDH-HRP conjugated antibodies were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). Densitometry analyses of luminescence images were performed using ImageJ (Wayne Rasband, NIH, USA), signal intensity values were normalized to GAPDH.

2.5. RNA extraction, reverse transcription and Quantitative Real-Time PCR Astrocyte cultures were treated with clomipramine for 4 days. RNA was extracted using RNeasy Micro kit (Qiagen, Hilden, Germany) according to the manufacturers protocol. 300 ng RNA were used for reverse transcription using iScript cDNA synthesis kit in a CFX 96 Real Time System (Bio-Rad). The primers for qPCR were designed using Primer 3 software (http://frodo.wi.mit.edu/primer3/input.htm), tested for primer dimers in Netprimer (Premier Biosoft International) and controlled for specificity using BLAST (NCBI, NIH) (Supplementary Table 1). They were designed to span introns when possible and qPCR product length was confirmed using agarose gel. Mastermix was prepared with iQ™SYBR Green Supermix (Bio-Rad). The qPCR experiments were performed in 384-well plates (4titude, Wotton, Surrey, UK) in a Lightcycler 480 instrument (Roche Diagnostics, Basel, Switzerland). Data analysis using GeNorm and Normfinder in GenEx Professional version 5.4.4 software (MultiD, Gothenburg, Sweden) showed that PPIA was the gene most stable, compared to ACTB, GAPDH, and PGK1, and was therefore used as reference gene. Relative expression for every sample was calculated using an estimated efficiency constant of 1.9 and the value was then normalized to the reference gene (Andersson et al. 2013, Pekny et al. 2014b).

2.6. Immunofluorescence Cell cultures were fixed for 20 min with 4% PFA at room temperature. Permeabilization and blocking of unspecific binding were performed in PBS containing 5% FBS and 0.5% Triton X-100 for 30 min at room temperature. Primary antibodies were used overnight at 4°C. Secondary antibodies were applied for 1 h at room temperature. Cells were washed 3 times for 5 min with PBS between incubations. Images for quantification were obtained in a Leica DMI6000 B fluorescence microscope (Leica Microsystems, Wetzlar, Germany).

7

2.7. Astrocyte proliferation Exponentially growing astrocyte cultures were labeled with 5 µM BrdU for 3 h and fixed 2 days later. Cells were sequentially incubated in 1 M HCl at 4°C for 10 min, 2 M HCl at room temperature for 10 min, 2 M HCl at 37°C for 20 min, 0.1 M borate buffer at room temperature for 12 min, and PBS supplemented with 5% FBS, 0.5% Triton X-100 for 30 min. Anti-BrdU (BU1/75, Nordic Biosite, Täby, Sweden) was incubated 1:200 overnight followed by Alexa Fluor 488 goat anti-Rat IgG (Molecular Probes, Life Technologies, Carlsbad, CA, USA) 1:1,500 1 h at room temperature. DAPI was used for visualizing all the nuclei. Images were taken from equivalent areas and positive cells counted using Image J.

2.8. Measurement of reactive oxygen species For measurement of H2O2-induced reactive oxygen species, cultures were incubated in HBSS with 50 µM DCFDA for 30 min followed by 30 min incubation in 100 µM H2O2 in HBSS. Fluorescence was measured using a Victor multilabel plate reader (Perkin Elmer) setting the excitation at 485 nm and emission at 535 nm. After measuring the fluorescence, cells were fixed with 4% PFA in PBS and stained with Coomassie blue R-250 (CBB, BDH laboratory Supplies, Poole, UK) solution (0.04% CBB, 25% ethanol and 12% acetic acid) for 1 h, followed by three washes with destaining solution (10% ethanol and 5% acetic acid) and resuspension in 1 M potassium acetate in 70% ethanol. CBB absorbance at 560 nm was used to normalize the fluorescence reading to the protein amount.

2.9. OGD OGD buffer contained 51 mM NaCl, 65 mM K-gluconate, 0.13 mM CaCl2, 1.5 mM MgCl2 and 10 mM HEPES pH 6.8. The buffer was deoxygenated using N2 for 30 min before cell treatment. Cells were incubated at 37 °C on a humidified incubator set to 1% O2, 5% CO2 and 94% N2. Reperfusion was induced by changing the media and returning the cells to standard culture conditions.

2.10. Assessment of cell death At the end of OGD, cultures were incubated in neurobasal supplemented with B27 for 2 h in regular culture conditions. Lactate dehydrogenase activity (LDH) was measured in the supernatant following manufacturer’s instructions (Takara Bio Inc., Shiga, Japan). Total LDH was measured after lysing the cells with 1% Triton X-100.

8

2.11. Neuronal measurements Neuronal cultures or astrocyte and neuronal co-cultures were fixed and neurons visualized by immunofluorescence against beta-III-tubulin (Tuj1, 1:2,000, Covance) followed by Alexa Fluor 488 goat anti-mouse IgG (Molecular Probes, Life Technologies, Carlsbad, CA, USA). Neuronal number was obtained by counting the beta-III-tubulin positive cells extending neurites at least longer than twice the cell body, and presented as percentage of the untreated sample. The longest neurite from each neuron was manually traced and measured using ImageJ. The total length of neurites was calculated using Volocity software (Improvision, Perkin Elmer, USA) as the sum of the length of all the neurites from all the neurons from each sample and presented as percentage of the untreated sample. The average neurite length per neuron was calculated for each sample as the total neurite length divided by the number of neurons.

2.12. Statistics Data are presented as the mean ± standard error of the mean. Two-tailed, non paired Student’s t-test followed by Bonferroni’s post hoc analysis was applied * p < 0.05, ** p < 0.01, *** p < 0.001. For experiments where a dose response is presented, twotailed, non paired Student’s t-test comparing each concentration with the untreated sample was used without post hoc correction # p < 0.05, ## p < 0.01, ### p < 0.001.

3. RESULTS 3.1. Clomipramine down-regulates GFAP, vimentin and nestin in astrocytes and does not impair the elimination of reactive oxygen species Clomipramine was previously reported to decrease GFAP expression in astrocyte cultures and mouse brain (Cho et al. 2010). Here, we assessed its effect on other intermediate filament proteins expressed in astrocytes, specifically vimentin and nestin. Astrocytes were cultured in the presence of clomipramine for 4 days. Clomipramine reduced the levels of vimentin and nestin as well as GFAP (Fig. 1A). A decrease in vimentin levels was observed in 70% of the samples (i.e. 21 out of 30 samples exposed to 5-12 µM clomipramine for 2 to 10 days); the same effect on GFAP and nestin protein was seen in 63% and 58% of the individual samples,

9

respectively (24 out of 38, and 19 out of 33, respectively). At the mRNA level, we observed an increase in the expression of GFAP, but not vimentin or nestin (Fig. 1B).

Clomipramine did not affect astrocyte survival at concentration up to 10 µM but induced a 57% cell death at a higher concentration (15 µM) (Fig. 1C). Clomipramine treatment did not affect astrocyte proliferation (Fig 1D). As intermediate filaments are mediators of cellular response to oxidative stress (de Pablo et al. 2013), we tested if treatment with clomipramine negatively affects astrocyte response to injury. The amount of reactive oxygen species after addition of hydrogen peroxide was not altered in the presence of 10 µM clomipramine (Fig. 1E). Similarly, cell death induced by 18 h of OGD followed by 2 h of standard culture conditions was not increased by the exposure to 3 or 10 µM clomipramine (Fig. 1F).

Jointly, these findings show that clomipramine decreases the amount of intermediate filament proteins GFAP, vimentin and nestin in astrocytes without affecting astrocyte resilience to oxidative stress.

3.2. Clomipramine is neurotoxic at concentrations that are well tolerated by astrocytes Next, we tested the toxicity of 2-day long treatment with clomipramine on primary enriched neuronal cultures starting on day 2 and 7 after plating (Fig. 2A). At 2 days after plating, neurons had attached, were extending long processes and could tolerate up to 4 µM of clomipramine. At 7 days in vitro, neurons had extended a dense neurite network and tolerated clomipramine up to 10 µM (Fig. 2A).

Treatment with epoxomicin up to 5 nM did not affect neuronal number when the treatment was started at 2 or 7 days after plating (Fig. 2B). Treatment with 0.5 µM withaferin A reduced the number of surviving neurons by 41% when added on day 2 after plating (Fig. 2C). Doses up to 1 µM withaferin A had no effect on neuronal survival when added at 7 days of culture (Fig. 2C).

10

3.3. Clomipramine and epoxomicin do not affect astrocyte resilience Next, we used the concentrations of clomipramine, epoxomicin and withaferin A that did not lead to substantial neuronal death and assessed LDH release after OGD and reperfusion. At these concentrations, clomipramine and epoxomicin had no detectable effect on protein levels of GFAP or vimentin in the soluble or filamentous (polymerized) fractions (Supplementary Fig. S1). Pretreatment of astrocytes with clomipramine or epoxomicin did not induce sensitization to OGD and reperfusion (Fig. 2E). Withaferin A, on the other hand, increased astrocyte cell death after OGD and reperfusion (Fig. 2E). To assess if this effect was mediated by intermediate filaments, we used astrocytes from GFAP–/–Vim–/– mice, which completely lack the cytoplasmic intermediate filaments (Eliasson et al. 1999, Pekny et al. 1999, Lepekhin et al. 2001). Identical increase in toxicity after treatment with withaferin A during OGD was observed in wild-type and GFAP–/–Vim–/– astrocytes, implying that withaferin A toxicity in vitro is not mediated by intermediate filaments (Fig. 2F). None of the drugs increased neuronal cell death induced by OGD and reperfusion in enriched neuronal cultures, and 2 µM clomipramine and 5 nM epoxomicin had a mild neuroprotective effect (Fig. 2D). These data show that astrocyte resilience to OGD is not affected by clomipramine or epoxomicin, whereas withaferin A sensitizes astrocytes to OGD through an intermediate filament-independent pathway.

3.4. Clomipramine and epoxomicin increase neurosupportive properties of astrocytes under standard culture conditions In vitro, silencing of GFAP in spinal cord astrocytes has been reported to promote better survival and neurite extension of co-cultured cortical neurons (Desclaux et al. 2009). Therefore, we tested whether pharmacological modulation of astrocyte reactivity had any effect on neuronal attachment/survival, and neurite extension. Neurons were plated on top of astrocyte monolayers pretreated for 24 h with clomipramine, epoxomicin or withaferin A, and 2 days later the total length of neurites was measured. We observed that epoxomicin and clomipramine increased the combined outcome of neuronal attachment/survival and neurite extension (Fig. 3B).

To

investigate

the

relative

contribution

of

neurite

extension

and

cell

attachment/survival to the above results, we counted the neurons, measured the

11

longest neurite per neuron and calculated the total neurite length per neuron. Epoxomicin and 0.5 µM clomipramine increased the number of neurons attaching and initiating neurite extension (Fig. 3A). None of the drugs altered the average neurite extension per neuron (Supplementary Fig. S2A), 5 nM epoxomicin decreased the average length of the longest neurite per cell (Supplementary Fig. S2B). Withaferin A, had no positive effect on any of these parameters and decreased neuronal survival at 1 µM (Fig. 3A-B). The addition of clomipramine and epoxomicin to enriched neuronal cultures did not affect neuronal number (Supplementary Fig. S3), indicating that the effect of the drugs on neuronal number is mediated by the presence of cocultured astrocytes. These results show that under standard culture conditions, clomipramine and epoxomicin but not withaferin A increase neurosupportive properties of astrocytes.

3.5. Epoxomicin increases neurosupportive properties of astrocytes after OGD Next, we tested if neuronal attachment/survival, and neurite extension were affected by administration of the drugs after an ischemic insult. Neurons were plated on top of astrocytes that had been subjected to OGD followed by 24 h of standard culture conditions with the drugs. Clomipramine did not show any effect on neuronal number or total length of neurites (Fig. 3C-D). Epoxomicin increased the combined outcome of attachment/survival, and neurite extension (Fig. 3D), and 1 nM epoxomicin increased the number of neurons (Fig. 3C). Pretreatment of astrocytes with epoxomicin prior to the addition of neurons was required for the increase in neuronal number (Fig. 3E) and in total neurite length (Fig. 3F). These results show that epoxomicin stimulates neurosupportive properties of astrocytes after ischemic stress.

DISCUSSION The beneficial aspects of reactive gliosis range from sequestration of the affected region of the CNS to active neuroprotection and regulation of CNS homeostasis after injury. If not resolved in time, i.e. within the post-acute or the early chronic stage after injury, reactive gliosis and glial scarring might have inhibitory effects on CNS 12

regeneration in some, albeit not all neuropathologies (Anderson et al. 2016, Pekny et al. 2014a). Experiments performed in mice with reactive gliosis attenuated by genetic ablation of GFAP and vimentin point to the intermediate filament system as a target for therapeutic intervention after CNS injury (Pekny & Pekna 2014). Pharmacological modulation of astrocyte intermediate filaments appears as a potentially attractive strategy to translate the beneficial effects observed in animal genetic models into therapeutics. In this study we used drugs reported to decrease GFAP levels to evaluate in vitro the feasibility of such an intervention to increase the neurosupportive properties of astrocytes without affecting astrocyte resilience to oxidative stress.

We report that moderate modulation of astrocyte intermediate filament system can be achieved without impairing astrocyte resilience to oxidative stress. In addition, clomipramine and epoxomicin had positive effect on the capacity of astrocytes to provide support to neurons. Whereas both drugs increased neuroprotective properties of astrocytes under standard culture conditions that are known to induce cellular stress (Puschmann et al. 2013), epoxomicin had this effect also on astrocytes subjected to ischemic stress. These results point to clomipramine and epoxomicin as possible candidates to promote neuronal survival and neurite extension in situations connected with cellular stress.

Our findings that treatment of astrocyte cultures with clomipramine reduces protein levels of GFAP as well as vimentin and nestin indicate that reactive gliosis is downregulated by clomipramine. Our results confirm and expand on the report from the Messing laboratory on the GFAP downregulating effects of clomipramine (Cho et al. 2010), as well as the Hol laboratory, who described the downregulating effect of epoxomicin on the expression of GFAP, vimentin and nestin in human glioblastoma cell lines, and on the expression of GFAP and vimentin in rat brains (Middeldorp et al. 2009). The mechanisms underlying the decrease in intermediate filament protein levels are not known, although our finding of increased GFAP mRNA levels in clomipramine treated astrocytes indicate that clomipramine increases intermediate filament protein degradation and/or inhibits mRNA translation.

We have also found that developing neurons were more sensitive to these drugs than mature neurons. For this reason, it is important to note that the positive effects of 13

clomipramine and epoxomicin on neurosupportive properties of astrocytes reported in this study were observed at doses that were well tolerated by developing neurons. We have shown that a 4 day treatment with low doses of clomipramine (up to 2 µM) and epoxomicin (up to 5 nM) did not induce a significant alteration in the intermediate filament protein levels (albeit 1 µM clomipramine increased GFAP mRNA levels), and did not affect astrocyte resilience to OGD. Both 1 and 5 nM epoxomicin and 0.5 µM clomipramine improved neuronal attachment and survival on top of pretreated astrocytes. Thus, clomipramine and epoxomicin promote the neurosupportive properties of astrocytes at concentrations below those that would induce a robust reduction in the overall amount of intermediate filament proteins in astrocytes. It is likely that clomipramine and epoxomicin affect the organization of intermediate filament proteins into intermediate filament bundles, their intracellular distribution, or the responsiveness of the intermediate filament system to the cell culture environment, which is known to constitute a substantial cellular stress (Andreasson et al. 2016, Puschmann et al. 2013, Puschmann et al. 2014). For example, the immunoreactivity and intracellular organization of the intermediate filament network in astrocytes can change in response to altered culture conditions and this response is independent of de novo synthesis of intermediate filament proteins (Oh et al. 1995). Other mechanisms, independent of the intermediate filament system, cannot be excluded. The exact mechanisms by which clomipramine and epoxomicin affect the expression, organization and functions of the intermediate filament system, and stimulate the neurosupportive properties of astrocytes warrant further investigation.

In contrast to clomipramine and epoxomicin, withaferin A, sensitized astrocytes to OGD-induced cell death, decreased neuronal adhesion and survival, and did not show any positive effect on astrocyte neurosupportive properties. As withaferin A directly binds soluble tetrameric GFAP and vimentin, affecting the filament organization already after 2 h treatment (Bargagna-Mohan et al. 2007, Bargagna-Mohan et al. 2010), it is possible that the negative effects of withaferin A on astrocyte resilience and their neurosupportive properties are mediated by its fast and disruptive interference with intermediate filament organization thus hampering the positive role of the intermediate filament system in handling the acute stress (Pekny & Pekna 2014). We have tested this hypothesis by using astrocytes devoid of the cytoplasmic intermediate filaments (Eliasson et al. 1999, Pekny et al. 1999, Lepekhin et al. 2001) 14

and our findings support the conclusion that the toxic effect of withaferin A on astrocytes was independent of intermediate filaments.

In summary, this study suggests that pharmacological modulation of the astrocyte intermediate filament system by epoxomicin and clomipramine can increase the neurosupportive properties of astrocytes without compromising their ability to cope with ischemic stress.

ACKNOWLEDGMENTS This work was supported by Swedish Medical Research Council (11548), ALF Gothenburg (11392), AFA Research Foundation, Söderberg’s Foundations, Sten A. Olsson Foundation for Research and Culture, Hjärnfonden, Hagströmer’s Foundation Millennium, Amlöv’s Foundation, E. Jacobson’s Donation Fund, Wilhelm and Martina Lundgrens Foundation, VINNOVA Health Program, the Swedish Stroke Foundation, the Swedish Society of Medicine, the Free Mason Foundation, Chalmers University of Technology, NanoNet COST Action (BM1002), EU FP 7 Program EduGlia (237956), EU FP 7 Program TargetBraIn (279017). The authors have no conflict of interest to declare.

FIGURE LEGENDS Figure 1. Clomipramine alters the expression of intermediate filament proteins in astrocytes and is not toxic to cultured astrocyte. Astrocyte cultures were treated with the indicated doses of clomipramine for 4 days. (A) Protein amount in total cell lysate was measured by Western blot analysis; n = 3, 4 and 2 independent cell preparations for GFAP, vimentin and nestin respectively. (B) mRNA was measured by RT-qPCR n = 4 cultures run in parallel. *p < 0.05, **p < 0.01, ***p < 0.001. (C) Clomipramine at concentrations up to 10 µM is not toxic to astrocyte cultures. Astrocyte cultures were treated for 4 days with the indicated doses of clomipramine and live cells were counted, n = 8 replicates, ###p < 0.001. (D) Proliferating cells were labeled with BrdU and all nuclei were labeled with DAPI. Cell proliferation is expressed as the

15

relative fraction of BrdU+ cells, n = 4 cultures performed in parallel. (E) Astrocyte cultures untreated (white bars) or pretreated with 10 µM clomipramine for 4 days (gray bars) were exposed to 100 µM H2O2 or maintained in regular media (Ctrl) for 30 min. Reactive oxygen species were measured at the end of the 30 min incubation, n = 4 cultures run in parallel. (F) Astrocytes pretreated with 0, 3 and 10 µM clomipramine were maintained in standard culture conditions (Ctrl) or incubated in OGD followed by 2 h of reperfusion (OGD). Cell death was measured as percentage of LDH released, n = 4 parallel cultures performed in paralel.

Figure 2. The analysis of clomipramine, epoxomicin and withaferin A toxicity. Neuronal cultures were treated with clomipramine (A), epoxomicin (B) and withaferin A (C). Treatments were started when the neurons had attached and started growing neurites (Day 2), or on mature cultures (Day 7). Neurons were counted after 2 days of treatment. #p < 0.05, ##p < 0.01, ###p < 0.001. Neuronal (D) and astrocyte (E) cultures were pretreated with 0.5 and 2 µM clomipramine (C0.5, C2), 1 and 5 nM epoxomicin (Ep1, Ep5) and 1 µM withaferin A (W1) for 24 h followed by OGD in the presence of the drugs. Cell death was measured as percentage of LDH release, n = 4 replicates. (F) Astrocyte cultures from wild-type mice (grey bars) and GFAP and vimentin deficient mice (GFAP–/–Vim–/–, white bars) were pre-treated with the indicated drugs for 24 h followed by OGD in the presence of drugs. LDH was measured at the end of 2 h reperfusion in normal culture conditions, n = 2 and 4 cultures run in parallel for wild-type and GFAP–/–Vim–/– respectively *p < 0.05, **p < 0.01, ***p < 0.001.

Figure 3. Modulation of astrocyte neurosupportive properties by clomipramine, epoxomicin and withaferin A. (A-B) Astrocyte neurosupportive properties under standard conditions. Neurons were plated on top of astrocytes pretreated with the drugs for 24 h. Co-cultures were maintained in the presence of the drugs for additional 48 h. Neuronal number (A) and total neurite extension (B) were determined. (C-D) Astrocyte neurosupportive properties after ischemia. Neuronal number (C) and total neurite length (D) of neurons plated on top of astrocytes subjected to OGD for 18 h followed by 24 h reperfusion. Drugs were added during astrocyte reperfusion and maintained during the co-culture with the neurons. C0.5 and C2, 0.5 and 2 µM clomipramine, respectively; Ep1 and Ep5, 1 and 5 nM epoxomicin, 16

respectievely; W0.25 and W1, 0.25 and 1 µM withaferin A. Neuronal number (E) and total neurite length (F) were measured as in C and D (white and gray bars) with the addition of epoxomicin only during the co-culture (no pretreatment, hatched bars). Data averaged from 3 separate cultures are presented. *p < 0.05, **p < 0.01, ***p < 0.001.

REFERENCES Anderson, M. A., Burda, J. E., Ren, Y. et al. (2016) Astrocyte scar formation aids central nervous system axon regeneration. Nature, 532, 195-200. Andersson, D., Wilhelmsson, U., Nilsson, M., Kubista, M., Stahlberg, A., Pekna, M. and Pekny, M. (2013) Plasticity response in the contralesional hemisphere after subtle neurotrauma: gene expression profiling after partial deafferentation of the hippocampus. PLoS One, 8, e70699. Andreasson, K. I., Bachstetter, A. D., Colonna, M. et al. (2016) Targeting innate immunity for neurodegenerative disorders of the central nervous system. J Neurochem, 138, 653-693. Bargagna-Mohan, P., Hamza, A., Kim, Y. E. et al. (2007) The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chemistry & biology, 14, 623-634. Bargagna-Mohan, P., Paranthan, R. R., Hamza, A. et al. (2010) Withaferin A targets intermediate filaments glial fibrillary acidic protein and vimentin in a model of retinal gliosis. J Biol Chem, 285, 7657-7669. Brenner, M., Johnson, A. B., Boespflug-Tanguy, O., Rodriguez, D., Goldman, J. E. and Messing, A. (2001) Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nature genetics, 27, 117-120. Cho, K. S., Yang, L., Lu, B., Feng Ma, H., Huang, X., Pekny, M. and Chen, D. F. (2005) Re-establishing the regenerative potential of central nervous system axons in postnatal mice. J Cell Sci, 118, 863-872. Cho, W., Brenner, M., Peters, N. and Messing, A. (2010) Drug screening to identify suppressors of GFAP expression. Human molecular genetics, 19, 3169-3178. Cho, W. and Messing, A. (2009) Properties of astrocytes cultured from GFAP overexpressing and GFAP mutant mice. Exp Cell Res, 315, 1260-1272. Colakoglu, G. and Brown, A. (2009) Intermediate filaments exchange subunits along their length and elongate by end-to-end annealing. J Cell Biol, 185, 769-777. Colucci-Guyon, E., Portier, M. M., Dunia, I., Paulin, D., Pournin, S. and Babinet, C. (1994) Mice lacking vimentin develop and reproduce without an obvious phenotype. Cell, 79, 679-694. de Pablo, Y., Nilsson, M., Pekna, M. and Pekny, M. (2013) Intermediate filaments are important for astrocyte response to oxidative stress induced by oxygenglucose deprivation and reperfusion. Histochemistry and cell biology, 140, 8191. Desclaux, M., Teigell, M., Amar, L., Vogel, R., Gimenez, Y. R. M., Privat, A. and Mallet, J. (2009) A novel and efficient gene transfer strategy reduces glial

17

reactivity and improves neuronal survival and axonal growth in vitro. PLoS One, 4, e6227. Eliasson, C., Sahlgren, C., Berthold, C. H., Stakeberg, J., Celis, J. E., Betsholtz, C., Eriksson, J. E. and Pekny, M. (1999) Intermediate filament protein partnership in astrocytes. J Biol Chem, 274, 23996-24006. Eriksson, J. E., He, T., Trejo-Skalli, A. V., Harmala-Brasken, A. S., Hellman, J., Chou, Y. H. and Goldman, R. D. (2004) Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. J Cell Sci, 117, 919-932. Goldman, J. E. and Yen, S. H. (1986) Cytoskeletal protein abnormalities in neurodegenerative diseases. Annals of neurology, 19, 209-223. Helfand, B. T., Chang, L. and Goldman, R. D. (2004) Intermediate filaments are dynamic and motile elements of cellular architecture. J Cell Sci, 117, 133-141. Herrmann, J. E., Imura, T., Song, B. et al. (2008) STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J Neurosci, 28, 72317243. Inagaki, M., Gonda, Y., Nishizawa, K. et al. (1990) Phosphorylation sites linked to glial filament disassembly in vitro locate in a non-alpha-helical head domain. J Biol Chem, 265, 4722-4729. Izmiryan, A., Cheraud, Y., Khanamiryan, L. et al. (2006) Different expression of synemin isoforms in glia and neurons during nervous system development. Glia, 54, 204-213. Jarlestedt, K., Rousset, C. I., Faiz, M. et al. (2010) Attenuation of reactive gliosis does not affect infarct volume in neonatal hypoxic-ischemic brain injury in mice. PLoS One, 5, e10397. Jing, R., Wilhelmsson, U., Goodwill, W., Li, L., Pan, Y., Pekny, M. and Skalli, O. (2007) Synemin is expressed in reactive astrocytes in neurotrauma and interacts differentially with vimentin and GFAP intermediate filament networks. J Cell Sci, 120, 1267-1277. Kinouchi, R., Takeda, M., Yang, L., Wilhelmsson, U., Lundkvist, A., Pekny, M. and Chen, D. F. (2003) Robust neural integration from retinal transplants in mice deficient in GFAP and vimentin. Nat Neurosci, 6, 863-868. Larsson, A., Wilhelmsson, U., Pekna, M. and Pekny, M. (2004) Increased cell proliferation and neurogenesis in the hippocampal dentate gyrus of old GFAP(-/-)Vim(-/-) mice. Neurochem Res, 29, 2069-2073. Lebkuechner, I., Wilhelmsson, U., Mollerstrom, E., Pekna, M. and Pekny, M. (2015) Heterogeneity of Notch signaling in astrocytes and the effects of GFAP and vimentin deficiency. J Neurochem, 135, 234-248. Lepekhin, E. A., Eliasson, C., Berthold, C. H., Berezin, V., Bock, E. and Pekny, M. (2001) Intermediate filaments regulate astrocyte motility. J Neurochem, 79, 617-625. Li, H., Guo, Y., Teng, J., Ding, M., Yu, A. C. and Chen, J. (2006) 14-3-3gamma affects dynamics and integrity of glial filaments by binding to phosphorylated GFAP. J Cell Sci, 119, 4452-4461. Li, L., Lundkvist, A., Andersson, D. et al. (2008) Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab, 28, 468-481. Liem, R. K. and Messing, A. (2009) Dysfunctions of neuronal and glial intermediate filaments in disease. J Clin Invest, 119, 1814-1824. Lundkvist, A., Reichenbach, A., Betsholtz, C., Carmeliet, P., Wolburg, H. and Pekny, M. (2004) Under stress, the absence of intermediate filaments from Muller

18

cells in the retina has structural and functional consequences. J Cell Sci, 117, 3481-3488. McLean, W. H. and Lane, E. B. (1995) Intermediate filaments in disease. Current opinion in cell biology, 7, 118-125. Menet, V., Prieto, M., Privat, A. and Gimenez y Ribotta, M. (2003) Axonal plasticity and functional recovery after spinal cord injury in mice deficient in both glial fibrillary acidic protein and vimentin genes. Proc Natl Acad Sci U S A, 100, 8999-9004. Middeldorp, J. and Hol, E. M. (2011) GFAP in health and disease. Progress in neurobiology, 93, 421-443. Middeldorp, J., Kamphuis, W., Sluijs, J. A. et al. (2009) Intermediate filament transcription in astrocytes is repressed by proteasome inhibition. FASEB J, 23, 2710-2726. Nakazawa, T., Takeda, M., Lewis, G. P. et al. (2007) Attenuated glial reactions and photoreceptor degeneration after retinal detachment in mice deficient in glial fibrillary acidic protein and vimentin. Invest Ophthalmol Vis Sci, 48, 27602768. Oh, T. H., Markelonis, G. J., Von Visger, J. R., Baik, B. and Shipley, M. T. (1995) Acidic pH rapidly increases immunoreactivity of glial fibrillary acidic protein in cultured astrocytes. Glia, 13, 319-322. Okada, S., Nakamura, M., Katoh, H. et al. (2006) Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med, 12, 829-834. Parpura, V., Heneka, M. T., Montana, V. et al. (2012) Glial cells in (patho)physiology. J Neurochem, 121, 4-27. Paulin, D., Huet, A., Khanamyrian, L. and Xue, Z. (2004) Desminopathies in muscle disease. J Pathol, 204, 418-427. Pekny, M., Eliasson, C., Chien, C. L., Kindblom, L. G., Liem, R., Hamberger, A. and Betsholtz, C. (1998) GFAP-deficient astrocytes are capable of stellation in vitro when cocultured with neurons and exhibit a reduced amount of intermediate filaments and an increased cell saturation density. Exp Cell Res, 239, 332-343. Pekny, M., Johansson, C. B., Eliasson, C. et al. (1999) Abnormal reaction to central nervous system injury in mice lacking glial fibrillary acidic protein and vimentin. J Cell Biol, 145, 503-514. Pekny, M., Leveen, P., Pekna, M., Eliasson, C., Berthold, C. H., Westermark, B. and Betsholtz, C. (1995) Mice lacking glial fibrillary acidic protein display astrocytes devoid of intermediate filaments but develop and reproduce normally. Embo J, 14, 1590-1598. Pekny, M. and Nilsson, M. (2005) Astrocyte activation and reactive gliosis. Glia, 50, 427-434. Pekny, M. and Pekna, M. (2014) Astrocyte Reactivity and Reactive Astrogliosis: Costs and Benefits. Physiological reviews, 94, 1077-1098. Pekny, M., Pekna, M., Messing, A., Steinhauser, C., Lee, J. M., Parpura, V., Hol, E. M., Sofroniew, M. V. and Verkhratsky, A. (2016) Astrocytes: a central element in neurological diseases. Acta Neuropathol, 131, 323-345. Pekny, M., Wilhelmsson, U. and Pekna, M. (2014a) The dual role of astrocyte activation and reactive gliosis. Neuroscience letters, 565, 30-38.

19

Pekny, T., Andersson, D., Wilhelmsson, U., Pekna, M. and Pekny, M. (2014b) Short general anaesthesia induces prolonged changes in gene expression in the mouse hippocampus. Acta anaesthesiologica Scandinavica, 58, 1127-1133. Potokar, M., Kreft, M., Li, L., Daniel Andersson, J., Pangrsic, T., Chowdhury, H. H., Pekny, M. and Zorec, R. (2007) Cytoskeleton and vesicle mobility in astrocytes. Traffic, 8, 12-20. Potokar, M., Stenovec, M., Gabrijel, M., Li, L., Kreft, M., Grilc, S., Pekny, M. and Zorec, R. (2010) Intermediate filaments attenuate stimulation-dependent mobility of endosomes/lysosomes in astrocytes. Glia, 58, 1208-1219. Prahlad, V., Yoon, M., Moir, R. D., Vale, R. D. and Goldman, R. D. (1998) Rapid movements of vimentin on microtubule tracks: kinesin-dependent assembly of intermediate filament networks. J Cell Biol, 143, 159-170. Puschmann, T. B., Zanden, C., De Pablo, Y., Kirchhoff, F., Pekna, M., Liu, J. and Pekny, M. (2013) Bioactive 3D cell culture system minimizes cellular stress and maintains the in vivo-like morphological complexity of astroglial cells. Glia, 61, 432-440. Puschmann, T. B., Zanden, C., Lebkuechner, I., Philippot, C., de Pablo, Y., Liu, J. and Pekny, M. (2014) HB-EGF affects astrocyte morphology, proliferation, differentiation, and the expression of intermediate filament proteins. J Neurochem, 128, 878-889. Sofroniew, M. V. (2009) Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci, 32, 638-647. Sofroniew, M. V. and Vinters, H. V. (2010) Astrocytes: biology and pathology. Acta Neuropathol, 119, 7-35. Spurny, R., Abdoulrahman, K., Janda, L., Runzler, D., Kohler, G., Castanon, M. J. and Wiche, G. (2007) Oxidation and nitrosylation of cysteines proximal to the intermediate filament (IF)-binding site of plectin: effects on structure and vimentin binding and involvement in IF collapse. J Biol Chem, 282, 81758187. Stahlberg, A., Andersson, D., Aurelius, J., Faiz, M., Pekna, M., Kubista, M. and Pekny, M. (2011) Defining cell populations with single-cell gene expression profiling: correlations and identification of astrocyte subpopulations. Nucleic acids research, 39, e24. Takemura, M., Gomi, H., Colucci-Guyon, E. and Itohara, S. (2002) Protective role of phosphorylation in turnover of glial fibrillary acidic protein in mice. J Neurosci, 22, 6972-6979. Vardjan, N., Gabrijel, M., Potokar, M. et al. (2012) IFN-gamma-induced increase in the mobility of MHC class II compartments in astrocytes depends on intermediate filaments. Journal of neuroinflammation, 9, 144. Widestrand, A., Faijerson, J., Wilhelmsson, U., Smith, P. L., Li, L., Sihlbom, C., Eriksson, P. S. and Pekny, M. (2007) Increased neurogenesis and astrogenesis from neural progenitor cells grafted in the hippocampus of GFAP-/- Vim-/mice. Stem Cells, 25, 2619-2627. Wilhelmsson, U., Bushong, E. A., Price, D. L., Smarr, B. L., Phung, V., Terada, M., Ellisman, M. H. and Pekny, M. (2006) Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury. Proc Natl Acad Sci U S A, 103, 17513-17518. Wilhelmsson, U., Faiz, M., de Pablo, Y. et al. (2012) Astrocytes negatively regulate neurogenesis through the Jagged1-mediated Notch pathway. Stem Cells, 30, 2320-2329.

20

Wilhelmsson, U., Li, L., Pekna, M. et al. (2004) Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic regeneration. J Neurosci, 24, 5016-5021. Wong, Z. R., Su, P. H., Chang, K. W., Huang, B. M., Lee, H. and Yang, H. Y. (2013) Identification of a rod domain-truncated isoform of nestin, Nes-SDelta107254, in rat dorsal root ganglia. Neuroscience letters, 553, 181-185. Worman, H. J. and Courvalin, J. C. (2002) The nuclear lamina and inherited disease. Trends in cell biology, 12, 591-598. Wunderlich, K. A., Tanimoto, N., Grosche, A., Zrenner, E., Pekny, M., Reichenbach, A., Seeliger, M. W., Pannicke, T. and Perez, M. T. (2015) Retinal functional alterations in mice lacking intermediate filament proteins glial fibrillary acidic protein and vimentin. FASEB J, 29, 4815-4828. Zhang, Y., Sloan, S. A., Clarke, L. E. et al. (2016) Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron, 89, 37-53.

21

A

GFAP

Total protein

Vimentin

1.5

1.5

Nestin

1.8

0

*

1.0

GFAP

*

1.0

7 12 µM

1.2

**

*

0.5

0.5

0.6

0.0

0.0

0.0

Vimentin Nestin GAPDH

0

12 µM

7

B

0

12 µM

7

GFAP 2.5

***

mRNA

2.0

0

7

12 µM

Vimentin

Nestin

1.5

2.0

*

**

1.5 1.0

1.5

1.0 1.0

0.5 0.5

0.5 0.0

0.0 0

7 µM

5

0.0 0

5

D

150 Cell number

1

100 ###

50

0 5

10

1

4

6

7 µM

5

40 30 20 10 0

15 µM

F

80

2

8

10 µM

30 Ctrl

OGD

25

60 Untreated Clomipramine (10 µM)

40 20 0

LDH release (%)

ROS (arbitrary units)

0

0 0

E

7 µM 50

BrdU+ nuclei (%)

C

1

20 15 10 5 0

Ctrl

H2O2

0

3

10

0

3

10 µM

Day 2

A

Day 7

160 Number of neurons

Clomipramine

140 120 100 80 60 40

###

20

###

0 0

B

2

4

6

8

10

0

2

4

6

8

10 µM

Number of neurons

Epoxomicin

120 100 ##

80

##

60 40 20 0 0

C

2

4

6

8

10

0

2

4

6

8

10 nM

Number of neurons

Withaferin A

120 100 80

## ###

##

60

###

40 20 ###

###

###

0

D

1

2

3

E LDH release (%)

LDH release (%)

80

60

40

20

4

*

**

5

0

1

2

3

4

F

80

***

60

40

20

0 Ep1 Ep5

W1

80

WT wild-type GV GFAP-/-Vim-/-

60

***

***

40

20

0

0 Ctrl C0.5 C2

5 µM

LDH release (%)

0

Ctrl C0.5 C2

Ep1 Ep5 W1

Ctrl

W1

Astrocytes pretreated with drugs, then neurons added

140

*

120 Neuronal number

**

B **

160

***

140

100

**

80 60 40

Total neurite length

A

20

***

**

***

120 100 80 60 40 20 0

0 Ctrl

C0.5

C2

Ep1

Ctrl

Ep5 W0.25 W1

C0.5

C2

Ep1

Ep5 W0.25 W1

Astrocytes exposed to OGD, then pretreated with drugs, then neurons added

C

140

D

*

160

***

140 Total neurite length

Neuronal number

120 100 80 60 40 20

120 100 80 60 40 20

0 Ctrl

C0.5

C2

Ep1

0

Ep5 W0.25 W1

Ctrl

C0.5

*

E

F

*

140

C2

Ep1

Ep5 W0.25 W1

*

160

***

140

100 80

untreated no pretreatment

60

pretreated

40 20

Total neurite length

120 Neuronal number

*

120 untreated no pretreatment

100 80

pretreated

60 40 20 0

0 Ctrl

Ep1

Ep1

Ctrl

Ep1

Ep1

Ep5

Ep5